Re: Farmas USA
ja,ja. mira el pre de THLD, con 250 cromos en 4$
CÓDIGO AMIGO
ja,ja. mira el pre de THLD, con 250 cromos en 4$
ya, pero lo que ya han roto, roto esta.
Desde que vendi mi negocio en 2011 y cobrado a plazos anuales ... cada año he pagado una cosa diferente, es increible. Aqui no hay quien haga planificacion financiera que valga. Por eso jamas me hare un plan de pensiones, a saber con que me encuentro dentro de 25 años ... quita, quita.
Conversación interesante con los de mi broker, para que vayamos aprendiendo consillas:
Yo: I don't understand my why order hasn't been executed
E: when exactly the order should have been executed?
Yo: at 08:47:40 when that other at 1.80 got executed
E: a moment
Yo:
http://www.nasdaq.com/es/symbol/oxgn/premarket
E: I see no trade for today
E: the trade you see
E: is a trade done outside the market
E: and then reported to the exchange
Yo: I think those kind of trades don't even appear in Nasdaq page
Yo: that is a premarket trade
E: it was done on exchange Direct Edge
E: not on ISLAND Nasdaq
E: trades need to be reported to the exchange
E: it is a public stock
Yo: that's not consistent with other information from other times with other stocks, but OK, I will investigate it. Thanks
E: it is the fact
E: the trade happened on Direct Edge not on Nasdaq
E: so your order cannot be filled on that trade
E: also you have a hidden order
E: so the order can execute only if Bid= your LMT or better
Yo: what happens it it is hidden?
Yo: it has always worked
Yo: could you explain please?
E: it has always worked when Bid = your LMT
E: in this case, the market did not trade at your LMT
E: so it works the same way
E: the trade at 1.80 is not a trade that can trigger your order
Es decir, que al margen de lo de las órdenes que nos endiñan y con que nos engañan a través de canales fuera de nuestro alcance las órdenes ocultas solo saltan si son iguales a tu precio. Si el precio de oferta es superior, cogen esa en lugar de la oculta. Mandan huevos.
PSTI
Le he perdido la pista en los últimos tiempos, pero por el foro de células he leído a un par que tienen expectativas en ella. Puede que sea el momento. A observar.
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21. It estimates EPS of $0.40 in 2017 and $1.25 in 2018.
Acceleron believes the company will make significant progress this year in its clinical pipeline including shortening the time to market for its first product, PLX cells for critical limb ischemia, currently in Phase 2 in Europe. New Adaptive Licensing legislation in the European Union allows for limited commercialization of cell therapies after a successful Phase 2 study. Pluristem has yet to disclose a timeline for approval, however.
As with any investment opportunity, retail investors should complete their own thorough due diligence before considering taking action.